ContraFect_LOGO_Web.jpg
ContraFect Reports Second Quarter 2021 Financial Results and Provides Business Update
August 13, 2021 07:30 ET | ContraFect Corporation
Multiple peer-reviewed journal publications and presentations at scientific forums drive value and recognition across the Company’s DLA portfolio Continued patient enrollment in ongoing...
ContraFect_LOGO_Web.jpg
ContraFect Announces Multiple Presentations of New Research Data From Its Pipeline of Direct Lytic Agents at the 31st ECCMID
July 19, 2021 07:31 ET | ContraFect Corporation
YONKERS, N.Y., July 19, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
ContraFect_LOGO_Web.jpg
ContraFect Appoints Gary Woodnutt, Ph.D. as Senior Vice President of Translational Sciences and Preclinical Development
June 17, 2021 07:31 ET | ContraFect Corporation
YONKERS, N.Y., June 17, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
ContraFect_LOGO_Web.jpg
ContraFect Invited to Present New Research Data From Its Pipeline of Direct Lytic Agents at World Microbe Forum
June 17, 2021 07:30 ET | ContraFect Corporation
YONKERS, N.Y., June 17, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
ContraFect_LOGO_Web.jpg
ContraFect Announces Multiple Publications on Exebacase, Including First Manuscript on Local Administration of Lysin for Potential Treatment of Prosthetic Joint Infections
May 26, 2021 07:30 ET | ContraFect Corporation
Exebacase showed the potential to be used in patients with chronic Staphylococci prosthetic knee infection (PKI) to reduce symptoms and improve function The observed clinical responses in patients...
ContraFect_LOGO_Web.jpg
ContraFect Reports First Quarter 2021 Financial Results and Provides Business Update
May 14, 2021 07:30 ET | ContraFect Corporation
Interim futility analysis from the Phase 3 DISRUPT study of exebacase evaluating treatment superiority is anticipated in H2 2021 BARDA contract award provides up to $86.8 million for exebacase...
ContraFect_LOGO_Web.jpg
ContraFect Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
March 30, 2021 07:30 ET | ContraFect Corporation
Exebacase Phase 3 DISRUPT study enrollment ongoing in patients with Staph aureus bloodstream infections; results from interim futility analysis anticipated in H2 2021 Biomedical Advanced Research...
ContraFect_LOGO_Web.jpg
ContraFect Corporation Announces Proposed Public Offering of Common Stock
March 17, 2021 16:01 ET | ContraFect Corporation
YONKERS, N.Y., March 17, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the...
ContraFect_LOGO_Web.jpg
ContraFect Announces BARDA Contract Award for Up to $86.8 Million and Provides Business Outlook
March 11, 2021 16:05 ET | ContraFect Corporation
BARDA to provide funding for the ongoing Phase 3 DISRUPT study of exebacase for the treatment of patients with Staph aureus bloodstream infections Results from the Phase 3 DISRUPT study interim...
ContraFect_LOGO_Web.jpg
ContraFect Announces Appointment of Dr. Jane F. Barlow to Board of Directors
February 11, 2021 07:00 ET | ContraFect Corporation
YONKERS, N.Y., Feb. 11, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs)...